Brokerages expect that Catalent Inc (NYSE:CTLT) will post $0.34 earnings per share for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Catalent’s earnings, with the lowest EPS estimate coming in at $0.30 and the highest estimate coming in at $0.36. Catalent reported earnings of $0.27 per share during the same quarter last year, which would indicate a positive year over year growth rate of 25.9%. The firm is scheduled to report its next earnings results on Monday, February 5th.
According to Zacks, analysts expect that Catalent will report full-year earnings of $1.60 per share for the current financial year, with EPS estimates ranging from $1.53 to $1.70. For the next fiscal year, analysts forecast that the business will post earnings of $1.83 per share, with EPS estimates ranging from $1.75 to $1.94. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Catalent.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 EPS.
Several equities research analysts have recently weighed in on CTLT shares. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Wells Fargo & Co reissued an “outperform” rating and issued a $39.00 target price (up previously from $30.00) on shares of Catalent in a research note on Thursday, August 31st. Royal Bank of Canada began coverage on shares of Catalent in a research report on Wednesday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. Finally, BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $44.44.
In other news, Director Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Zions Bancorporation bought a new stake in Catalent during the third quarter valued at about $100,000. Acrospire Investment Management LLC boosted its stake in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares during the period. Quantbot Technologies LP boosted its stake in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares during the period. Fortaleza Asset Management Inc. bought a new position in Catalent during the third quarter valued at approximately $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares during the period. Institutional investors own 99.37% of the company’s stock.
Catalent (NYSE CTLT) traded down $0.33 during midday trading on Tuesday, reaching $41.08. 513,227 shares of the company’s stock traded hands, compared to its average volume of 908,045. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. Catalent has a one year low of $25.51 and a one year high of $43.39. The firm has a market capitalization of $5,515.00, a P/E ratio of 47.22, a PEG ratio of 2.67 and a beta of 1.41.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/catalent-inc-ctlt-expected-to-post-earnings-of-0-34-per-share.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.